Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Completed · Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.

Key facts

Study ID

NCT00273312

Run by

Novartis Pharmaceuticals

People needed

25

Starts

2006-01-01

Last updated by the study team

2017-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hepatocellular carcinoma patients with at least 1 previously un-irradiated, measurable lesion without any systemic single agent or combination chemotherapy. Previous local therapy is allowed.

You may not qualify if…

• Additional protocol-defined inclusion/exclusion criteria apply.

Where it is running

• Novartis Investigative Site — San Francisco, California, United States
• Novartis Investigative Site — Hong Kong, Shatin, NT, Hong Kong
• Novartis Investigative Site — Hong Kong, Hong Kong
• Novartis Investigative Site — Seoul, Korea, South Korea
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Taipei, Taiwan ROC, Taiwan
• Novartis Investigative Site — Tai Chung Municipality, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.